IXHL - Incannex wins FDA OK to trial cannabinoid-based sleep apnea drug
2023-08-22 10:22:39 ET
More on Incannex
- Incannex Healthcare to redomicile from Australia to US, list on Nasdaq
- Incannex rises 9% after Australia approval to begin phase 1 trial of anti-inflammatory drug
- Incannex adds over 19% with positive data for sleep apnea candidate
- Incannex to acquire APIRx Pharma in a deal worth over $93 million
- Seeking Alpha’s Quant Rating on Incannex Healthcare
For further details see:
Incannex wins FDA OK to trial cannabinoid-based sleep apnea drug